Focused On-demand Library for Mitotic spindle assembly checkpoint protein MAD1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9Y6D9

UPID:

MD1L1_HUMAN

Alternative names:

Mitotic arrest deficient 1-like protein 1; Mitotic checkpoint MAD1 protein homolog; Tax-binding protein 181

Alternative UPACC:

Q9Y6D9; B3KR41; Q13312; Q75MI0; Q86UM4; Q9UNH0

Background:

Mitotic spindle assembly checkpoint protein MAD1, also known as Mitotic arrest deficient 1-like protein 1, plays a crucial role in the spindle-assembly checkpoint, ensuring proper chromosome alignment before cell division. It forms a complex with MAD2L1, regulating the transition from metaphase to anaphase, thus preventing aneuploidy.

Therapeutic significance:

MAD1's involvement in mosaic variegated aneuploidy syndrome 7 highlights its potential as a target for therapeutic strategies aimed at mitigating chromosomal instability and tumor predisposition. Understanding the role of Mitotic spindle assembly checkpoint protein MAD1 could open doors to potential therapeutic strategies.